| P2093 | author name string | Girish J Kotwal | |
| P2860 | cites work | Smallpox as a Biological Weapon | Q22918878 |
| | CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 |
| | Internal homologies of the Ba fragment from human complement component Factor B, a class III MHC antigen | Q24555650 |
| | Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans | Q27629908 |
| | Three-dimensional structure of a complement control protein module in solution | Q27649903 |
| | Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins | Q28297889 |
| | Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy | Q30230715 |
| | Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel [...] | Q33805943 |
| | Poxviral mimicry of complement and chemokine system components: what's the end game? | Q33899303 |
| | Immunization against potential biological warfare agents | Q33958189 |
| | An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection | Q33987538 |
| | Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement | Q34066011 |
| | Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins | Q34069057 |
| | Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara | Q34343169 |
| | Virokines: novel immunomodulatory agents | Q34451942 |
| | Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation | Q34829635 |
| | Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein | Q35155228 |
| | Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines | Q35635459 |
| | Growing poxviruses and determining virus titer | Q35758633 |
| | Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza | Q35868774 |
| | Developing new smallpox vaccines | Q37075201 |
| | Structure of transglutaminases. | Q37594672 |
| | Target pattern recognition by complement proteins of the classical and alternative pathways | Q37607220 |
| | Phenotypic and genetic diversity of the traditional Lister smallpox vaccine | Q39908403 |
| | Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses | Q40122904 |
| | Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation | Q40308484 |
| | Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge | Q40326131 |
| | Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation | Q40578979 |
| | Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin | Q41021966 |
| | Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein | Q41188642 |
| | Purification of virokines using ultrafiltration | Q41446528 |
| | Regulation of complement activity by vaccinia virus complement-control protein | Q41897178 |
| | Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alte | Q43882885 |
| | Inhibition of the complement cascade by the major secretory protein of vaccinia virus | Q45006765 |
| | Vaccinia virus complement control protein ameliorates collagen-induced arthritic mice | Q45421141 |
| | Vaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis | Q45667851 |
| | Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation | Q45723011 |
| | Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions | Q45731552 |
| | Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells | Q45737584 |
| | The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation | Q45753724 |
| | Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. | Q45755897 |
| | The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein | Q45763563 |
| | Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis | Q45785869 |
| | Dissecting Sites Important for Complement Regulatory Activity in Membrane Cofactor Protein (MCP; CD46) | Q57936817 |
| | Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function | Q64449897 |
| | Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement | Q71151732 |
| | The purification fo four strains of poxvirus | Q76491615 |
| P433 | issue | 12 | |
| P921 | main subject | glycosylation | Q898365 |
| | Vaccinia virus | Q1986297 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 1084-1092 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Protein & Cell | Q26854012 |
| P1476 | title | Influence of glycosylation and oligomerization of vaccinia virus complement control protein on level and pattern of functional activity and immunogenicity | |
| P478 | volume | 1 | |